Bioavailability Containment Contract Manufacturing Development 
Pharmaceutical Technology
JUNE 14, 2023
This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Premium specialized equipment is necessary because high containment facilities call for the separation of the operator from the product.
Pharmaceutical Technology
APRIL 12, 2023
Evidence suggests that API manufacturing is gaining in complexity, as well as sophistication, and therefore adding to the risk profile of drug development. Currently mostly outsourced, there are signs that CMOs are beginning to make investments in containment capabilities, to capture emerging opportunities.
The Pharma Data
JANUARY 27, 2021
Construction of commercial drug manufacturing facility in Germany. Development of oral biosensor and contract development & manufacturing. Psychedelic transdermal and sublingual drug formulation development.
Expert insights. Personalized for you.
130 
Let's personalize your content